NMDA receptors antagonists alleviated the acute phase of traumatic brain injury.

Objectives: Traumatic brain injury (TBI) is a significant cause of mortality and disability worldwide. TBI has been associated with factors such as oxidative stress, neuroinflammation, and apoptosis, which are believed to be mediated by the N-methyl-D-aspartate (NMDA)-type glutamate receptor. Two NMDA receptor antagonists, ketamine and memantine, have shown potential in mitigating the pathophysiological effects of TBI.

Safety and Efficacy of BioMime Sirolimus-Eluting Stent System in All-Comers Real-World Population With Coronary Artery Stenosis: MILES Global Registry.

Background: This study evaluated the safety and efficacy of BioMime sirolimus-eluting stent (SES) system, with an ultra-low strut thickness (65 µm), in real-world all-comers population with coronary artery stenosis (CAD).

Methods: This was a post-marketing, multicenter, single-arm, observational clinical registry among patients undergoing intervention for CAD. Patients were clinically followed up at 1, 9, 12, and 24 months after the index percutaneous coronary intervention.

Experimental and Theoretical Investigations for Revealing the Influence of Cyclometalated Ligand Type on Protonolysis of Pt-Carbon Sites.

This study investigates possible pathways arising from the reaction of anionic K[Pt(C^N)(-MeCH)(CN)] complexes, C^N = 2-phenylpyridinate (ppy) and 7,8-benzo[h]quinolate (bzq), with trifluoroacetic acid (TFA), which has been employed in both experimental and computational approaches. Experimental studies clarify that the products of the protonolysis reaction can vary in the K[Pt(C^N)(-MeCH)(CN)] complex depending on the type of the cyclometalated ligand. In the cyclometalated complex with ppy, only one product was observed, resulting from the cleavage of the Pt-C bond of the cyclometalated ligand.

Intranasal esketamine for patients with major depressive disorder: A systematic review and meta-analysis.

A large number of people worldwide grapple with Major Depressive Disorder (MDD), and a significant portion of them confront resistance to conventional antidepressant treatments. Esketamine, an innovative intervention, has garnered attention due to its rapid-acting antidepressant effects. This meta-analysis aimed to evaluate the efficacy and safety of esketamine in individuals with MDD and Treatment-Resistant Depression (TRD).